Stability of Desmopressin Loaded in Liposomes

Journal of Liposome Research

Volumn 13, Issue 3-4, 2003, Pages 269-277

  Law, S L ^a   Huang, K J ^a   Chou, V H Y ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Degradation; Desmopressin; Half lives; Liposomes; Chymotrypsin

Indexed keywords

CHOLESTEROL; CHYMOTRYPSIN A; DESMOPRESSIN; DIOLEOYLPHOSPHATIDYLCHOLINE; LIPOSOME; OCTADECYLAMINE;

ARTICLE; COMPARATIVE STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; KINETICS; PH; PRIORITY JOURNAL;

EID: 0345714862     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.1081/LPR-120026392     Document Type: Article

References (17)

1. Vilhardt H. Basic pharmacology of desmopressin: a review. Drug Invest 1990; 2(suppl. 5):2-8.
2. Law SL, Huang KJ, Chou HY. Preparation of desmopressin-containing liposomes for intranasal delivery. J Con Rel 2001; 70:375-382.
3. Kahns AH, Buur A, Bundgaard H. Prodrugs of peptides. 18. Synthesis and evaluation of various esters of desmopressin (dDAVP). Pharm Res 1993; 10:68-74.
4. Sedlak D, Szymkowiak J, Saar A, Owen A. Stability of desmopressin in microemulsion formulations with soft gelatin capsules. Proc Con Rel Soc 1999; 26:911-912.
5. Rinderknecht H, Fleming RM. A new, highly sensitive and specific assay for chymotrypsin. Clin Chim Acta 1980; 59:139-146.
6. Lundin S, Bengtsson HI, Folkesson HG, Westrom BR. Degradation of [mercapopropionic acid 1, D-arginine 8]-vasopressin (dDAVP) in pancreatic juice and intestinal mucosa homogenate. Pharmacol Toxicol 1989; 65:92-95.
7. Lang JK. Quantitative determination of cholesterol in liposome drug products and raw materials by high-performance liquid chromatograpy. J Chrom 1990; 507:157-163.
8. Grit M, Crommelin DJA, Lang J. Determination of phosphatidylcholine, phosphatidylglycerol, and their lyso forms from liposome dispersions by high-performance liquid chromatography using high-sensitivity refractive index detection. J Chrom 1991; 585:239-246.
9. Zhou XH, Li Wan Po A. Peptide and protein drugs: I. Therapeutic applications, absorption, and parenteral administration. Int J Pharm 1991; 75:97-115.
10. Law SL, Shih CL. Characterization of calcitonin-containing liposome formulations for intranasal delivery. J Microencap 2001; 18:211-221.
11. Lee KC, Lee YJ, Song HM, Chun CJ, DeLuca PP. Degradation of synthetic salmon calcitonin in aqueous solution. Pharm Res 1992; 9:1521-1523.
12. Patel K, Borchardt RT. Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide. Pharm Res 1990; 7:703-711.
13. Helm VJ, Muller BW. Stability of gonadorelin and triptorelin in aqueous solution. Pharm Res 1990; 7:1253-1256.
14. Powell MF, Sanders LM, Rogerson A, Si V. Parenteral peptide formulations: chemical and physical properties of native luteinizing hormone-releasing hormone (LHRH) and hydrophobic analogues in aqueous solution. Pharm Res 1991; 8:1258-1263.
15. Fredholt K, Ostergaard J, Savolainen J, Friis GJ. α -Chymotrypsin-catalyzed degradation of desmopressin (dDAVP): influence of pH, concentration, and various cyclodextrins. Int J Pharm 1999; 178:223-229.
16. Weingaarten C, Moufti A, Delattre J, Puisieux F, Couvreur P. Protection of insulin from enzymatic degradation by its association to liposomes. Int J Pharm 1985; 26:251-257.
17. Kato Y, Hosokawa T, Hayakawa E, Ito K. Influence of liposomes on tryptic digestion of insulin. Biol Pharm Bull 1993; 16:457-461.